Curry M et al. Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO. (Abstract THU-127),Cornberg M et al. Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry Network.
Rilpivirine remt leverfibrose door selectieve STAT1-gemedieerde apoptose van hepatische stellaatcellen
apr 2020 | Hepatologie, HIV, Virale infecties